Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDORIL 15 vs AMTURNIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.
Hypertension
Hypertension,Edema due to congestive heart failure,Edema due to hepatic cirrhosis,Edema due to nephrotic syndrome,Edema due to corticosteroid or estrogen therapy
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
10 mg to 20 mg orally once daily, with or without food.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Terminal elimination half-life is 12 hours (range 10–14 hours); steady-state achieved within 2–3 days.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Amiloride is not metabolized and is excreted unchanged in the urine. Hydrochlorothiazide is not extensively metabolized; the majority is excreted unchanged in the urine via renal tubular secretion.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Primarily renal excretion as unchanged drug (70%) and glucuronide conjugate (15%); biliary/fecal elimination accounts for 10%.
~90%, primarily to albumin
98% bound to albumin and alpha-1-acid glycoprotein.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Vd = 0.15–0.25 L/kg; indicates primarily extracellular distribution.
Oral: 50–60% (extensive first-pass metabolism)
Oral: 40–50% due to first-pass metabolism.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR 15-29 m L/min/1.73 m²: reduce dose to 10 mg once daily. e GFR <15 m L/min/1.73 m² or dialysis: not recommended.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 10 mg once daily. Child-Pugh C: not recommended.
Not recommended for pediatric use; safety in children under 12 years not established.
Safety and efficacy not established; no recommended dose.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
No specific dose adjustment required, but monitor renal function closely due to age-related decline.
None
No FDA boxed warning.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hyperkalemia: Risk is increased in patients with renal impairment, diabetes, or elderly. Monitor serum potassium levels.,Hypersensitivity reactions: May occur with sulfonamide derivatives (hydrochlorothiazide).,Acute angle-closure glaucoma: Has been reported with sulfonamide derivatives.,Electrolyte imbalances: Including hyponatremia, hypochloremia, hypomagnesemia, and hypokalemia.,Renal impairment: Use with caution; may precipitate azotemia.,Hepatic impairment: Use with caution; may precipitate hepatic encephalopathy.,Diabetes: Thiazides may impair glucose tolerance.,Gout: Thiazides may increase serum uric acid levels.,SLE exacerbation: Thiazides may exacerbate systemic lupus erythematosus.
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Anuria,Acute or chronic renal insufficiency,Severe renal impairment (e GFR <30 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs,Concomitant use with potassium-sparing diuretics, potassium supplements, or other drugs that increase potassium (e.g., ACE inhibitors, ARBs)
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Administration with food decreases absorption and may reduce efficacy. Take at least 30 minutes before a meal. No specific food-drug interactions reported.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
FDA Pregnancy Category C. In animal studies, amturnide (finerenone) caused embryofetal toxicity (reduced fetal body weight, delayed ossification, and increased resorptions) at maternal toxic doses. There are no adequate human studies. Risk cannot be ruled out; use only if potential benefit justifies potential risk. First trimester: unknown risk. Second/third trimester: potential for fetal renal effects due to mineralocorticoid receptor blockade.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No data on presence in human milk. Finerenone and its metabolites are excreted in rat milk. M/P ratio not determined in humans. Due to potential for serious adverse reactions in nursing infants (e.g., hyperkalemia, hypotension), breastfeeding is not recommended during therapy.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
No specific dose adjustments established. Pharmacokinetics may be altered due to increased volume of distribution and renal plasma flow; however, no data exist. Use lowest effective dose if essential. Monitor for hyperkalemia and hypotension, which may require dose reduction or discontinuation.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
AMTURNIDE is a first-in-class guanylate cyclase-C receptor agonist for irritable bowel syndrome with constipation (IBS-C). It increases intestinal fluid secretion and transit without significant systemic absorption. Onset of action may occur within 24 hours, but full response may take 2-4 weeks. Avoid in patients with known or suspected mechanical gastrointestinal obstruction. Dose adjustment not required for renal or hepatic impairment.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
Take once daily on an empty stomach at least 30 minutes before the first meal of the day.,Do not crush or chew the capsule; swallow whole with water.,Common side effects include diarrhea, abdominal pain, and flatulence; diarrhea is most frequent.,Seek medical attention if you experience severe or bloody diarrhea.,Notify your doctor if you are pregnant, breastfeeding, or have a history of bowel obstruction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDORIL 15 vs AMTURNIDE, answered by our medical review team.
ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. AMTURNIDE is a Antihypertensive Combination that works by AMTURNIDE is a combination of amiloride, a potassium-sparing diuretic that inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium chloride reabsorption in the distal convoluted tubule. The combination produces additive diuretic and antihypertensive effects with reduced potassium loss.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDORIL 15 and AMTURNIDE depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. The standard adult dose of AMTURNIDE is: 10 mg to 20 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDORIL 15 and AMTURNIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . AMTURNIDE is classified as Category C. FDA Pregnancy Category C. In animal studies, amturnide (finerenone) caused embryofetal toxicity (reduced fetal body weight, delayed ossification, and increased resorptions) at mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.